Compass Pathways Advances Psilocybin Research in the UK

LOS ANGELES- Compass Pathways, a biotechnology company specializing in mental health innovations, has commenced the UK segment of its global Phase 3 clinical trial evaluating COMP360 psilocybin therapy for treatment-resistant depression (TRD). This initiative follows approval from the UK’s Medicines and Healthcare products Regulatory Agency.

The Phase 3 program comprises two pivotal trials: COMP 005 and COMP 006. The COMP 006 trial, now active in the UK, will assess three dosage levels of COMP360 (25mg, 10mg, and 1mg) across multiple research sites, including the newly established Centre for Mental Health Research and Innovation in London.

The Centre for Mental Health Research and Innovation, officially opened on November 15, 2023, is a collaborative effort between Compass Pathways, the South London and Maudsley NHS Foundation Trust, and the Institute of Psychiatry, Psychology & Neuroscience at King’s College London. The facility aims to accelerate psychedelic research and develop new mental health care models within the UK.

Compass Pathways’ Phase 3 program is the largest randomized, controlled, double-blind psilocybin treatment clinical trial conducted to date, building on promising results from its earlier Phase 2b study. The company is dedicated to developing innovative treatments for mental health conditions, with a focus on ensuring broad and equitable access upon regulatory approval.

David Bradley, Chief Executive of South London and Maudsley NHS Foundation Trust, expressed enthusiasm for the collaboration, stating that the partnership aims to develop innovative treatments to improve mental health care across the UK.

Compass Pathways continues to expand its research efforts, with the UK playing a significant role in its global strategy to address treatment-resistant depression through psilocybin-based therapies.